ArticleDiabetology & metabolic syndrome2024

Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway.

Jingshu Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.